Aethlon Medical (NASDAQ:AEMD) Share Price Crosses Below 200 Day Moving Average – Should You Sell?

Aethlon Medical, Inc. (NASDAQ:AEMD)’s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.15 and traded as low as $0.6830. Aethlon Medical shares last traded at $0.6940, with a volume of 214,260 shares.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Aethlon Medical has a consensus rating of “Reduce”.

Aethlon Medical Stock Performance

The stock has a market cap of $1.64 million, a price-to-earnings ratio of -0.05 and a beta of 1.41. The business’s fifty day simple moving average is $1.84 and its 200 day simple moving average is $2.15.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC purchased a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.